TerraPower Isotopes leadership, elected officials and key partners break ground on the Bellwether Laboratory, the company's flagship actinium-225 manufacturing facility in Philadelphia
TerraPower Isotopes leadership, elected officials and key partners break ground on the Bellwether Laboratory, the company's flagship actinium-225 manufacturing facility in Philadelphia
Hand-out
TPI Isotopes Logo (PRNewsfoto/TerraPower Isotopes)
$450 million East Coast flagship cGMP facility will increase Ac-225 production capacity twentyfold, supporting the next generation of cancer therapiesÂ
PHILADELPHIA, May 6, 2026 /PRNewswire/ -- TerraPower Isotopes® (TPI), part of TerraPower, a nuclear innovation company that advances transformative technologies across both energy and healthcare, broke ground today on its flagship Bellwether Laboratory—a 250,000-square-foot actinium-225 (Ac-225) manufacturing facility located in the Bellwether District of Philadelphia. The groundbreaking marks the next major milestone in TPI's journey to establish a state-of-the-art East Coast manufacturing presence dedicated to the production of one of the rarest and most medically promising isotopes to support the development of targeted alpha therapy and precision medicine.